EGFR and non-small cell lung carcinoma: In advanced NSCLC, the first-line regimen was platinum-based chemotherapy (cisplatin or carboplatin) for fifty-two patients, and anti-EGFR tyrosine-kinase-inhibitor therapy for four patients with mutated EGFR.